Related references
Note: Only part of the references are listed.Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
Matthias Rau et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
Jesper Jensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Milton Packer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C. David Mazer et al.
CIRCULATION (2020)
SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
So Ra Kim et al.
NATURE COMMUNICATIONS (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects
Motoaki Sano et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
Francesco Prattichizzo et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
Francesco Prattichizzo et al.
DIABETES OBESITY & METABOLISM (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
Ben A. Kappel et al.
CIRCULATION (2017)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Inhibition of Erythropoietin Production by Cytokines
WOLFGANG E. B. JELKMANN et al.
Annals of the New York Academy of Sciences (2010)
Share Paper
